About: Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial
Creator	Li, Xin Lin, Peng Gong, Jing Huang, Ling Fan, Kai-Liang Geng, Shu-Ying Hou, Ming Li, Mei-Feng Li, Xiao-Li Liang, Ya-Feng Liu, Lu-Yi Peng, Jun Qiu, Ji-Hua Tian, Xing-Han Wang, Li-Na Wang, Wen-Ting Yu, Qing-Xia Yu, Ying-Yi Zhang, Xiao-Lu Zhang, Yuan-Feng
source	PMC
abstract	BACKGROUND: Studies in murine models suggested that platelet desialylation was an important mechanism of thrombocytopenia during sepsis. METHODS: First, we performed a prospective, multicenter, observational study that enrolled septic patients with or without thrombocytopenia to determine the association between platelet desialylation and thrombocytopenia in patients with sepsis, severe sepsis, and septic shock. Gender- and age-matched healthy adults were selected as normal controls in analysis of the platelet desialylation levels (study I). Next, we conducted an open-label randomized controlled trial (RCT) in which the patients who had severe sepsis with thrombocytopenia (platelet counts ≤50 × 10(9)/L) were randomly assigned to receive antimicrobial therapy alone (control group) or antimicrobial therapy plus oseltamivir (oseltamivir group) in a 1:1 ratio (study II). The primary outcomes were platelet desialylation level at study entry, overall platelet response rate within 14 days post-randomization, and all-cause mortality within 28 days post-randomization. Secondary outcomes included platelet recovery time, the occurrence of bleeding events, and the amount of platelets transfused within 14 days post-randomization. RESULTS: The platelet desialylation levels increased significantly in the 127 septic patients with thrombocytopenia compared to the 134 patients without thrombocytopenia. A platelet response was achieved in 45 of the 54 patients in the oseltamivir group (83.3%) compared with 34 of the 52 patients in the control group (65.4%; P = 0.045). The median platelet recovery time was 5 days (interquartile range 4–6) in the oseltamivir group compared with 7 days (interquartile range 5–10) in the control group (P = 0.003). The amount of platelets transfused decreased significantly in the oseltamivir group compared to the control group (P = 0.044). There was no difference in the overall 28-day mortality regardless of whether oseltamivir was used. The Sequential Organ Failure Assessment score and platelet recovery time were independent indicators of oseltamivir therapy. The main reason for all of the mortalities was multiple-organ failure. CONCLUSIONS: Thrombocytopenia was associated with increased platelet desialylation in septic patients. The addition of oseltamivir could significantly increase the platelet response rate, shorten platelet recovery time, and reduce platelet transfusion. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR-IPR-16008542. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-017-0476-1) contains supplementary material, which is available to authorized users.
has issue date	2017-05-11(xsd:dateTime)
bibo:doi	10.1186/s13045-017-0476-1
bibo:pmid	28494777
has license	cc-by
sha1sum (hex)	3baa7122457d2de2a241921d2538914f496b118d
schema:url	https://doi.org/10.1186/s13045-017-0476-1
resource representing a document's title	Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial
has PubMed Central identifier	PMC5426054
has PubMed identifier	28494777
schema:publication	J Hematol Oncol
resource representing a document's body	covid:3baa7122457d2de2a241921d2538914f496b118d#body_text
is schema:about of	named entity 'platelet' named entity 'IMPORTANT' named entity 'suggested' named entity 'thrombocytopenia' named entity 'sepsis' named entity 'sepsis' named entity 'desialylation' named entity 'thrombocytopenia' named entity 'sepsis' named entity 'Platelet' named entity 'oseltamivir' named entity 'desialylation' named entity 'oseltamivir' named entity '19, 20' named entity 'thrombocytopenia' named entity 'mortality rate' named entity 'infection' named entity 'Multivariate analysis' named entity 'APACHE II' named entity 'multivariate analysis' named entity 'control group' named entity 'oseltamivir' named entity 'lectin' named entity 'oseltamivir' named entity 'galactose' named entity 'continuous renal replacement therapy' named entity 'log-rank test' named entity 'life span' named entity 'control group' named entity 'control group' named entity 'platelet' named entity 'septic shock' named entity 'Physiology' named entity 'proportional hazards regression' named entity 'blood platelet' named entity 'infection' named entity 'oseltamivir' named entity 'multivariate analysis' named entity 'septic shock' named entity 'risk factors' named entity 'platelet' named entity 'galactose' named entity 'murine models' named entity 'oseltamivir' named entity 'sepsis' named entity 'antimicrobial therapy' named entity 'oseltamivir' named entity 'mammalian cells' named entity 'control groups' named entity 'glycoproteins' named entity 'platelet' named entity 'desialylation' named entity 'control group' named entity 'control group' named entity 'sepsis' named entity 'oseltamivir' named entity 'control group' named entity 'antimicrobial therapy' named entity 'desialylation' named entity 'desialylation' named entity 'Chicago' named entity 'oseltamivir'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software